Physicochemical characterization of chitosan-hyaluronan-coated solid lipid nanoparticles for the targeted delivery of paclitaxel: A proof-of-concept study in breast cancer cells

Nanomedicine

Volumn 12, Issue 5, 2017, Pages 473-490

  Campos, Javier ^a   Varas Godoy, Manuel ^a   Haidar, Ziyad Samir ^a  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

Author keywords

chitosan; drug delivery; hyaluronan; layer by layer; multidrug resistance; nanoncology; paclitaxel; solid lipid nanoparticles

Indexed keywords

CHITOSAN; HYALURONAN RECEPTOR; HYALURONIC ACID; MEMBRANE RECEPTOR; NANOCARRIER; PACLITAXEL; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; LIPID; NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CHEMICAL PROCEDURES; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SELECTIVITY; DRUG TARGETING; DRUG UPTAKE; HIGH-PRESSURE HOT HOMOGENIZATION; HUMAN; HUMAN CELL; MATERIAL COATING; MCF-7 CELL LINE; MOLECULAR STABILITY; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; ZETA POTENTIAL; BREAST NEOPLASMS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; FEMALE; PATHOLOGY;

BREAST NEOPLASMS; CELL SURVIVAL; CHITOSAN; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; HUMANS; HYALURONIC ACID; LIPIDS; MCF-7 CELLS; NANOPARTICLES; PACLITAXEL;

EID: 85012863112     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0371     Document Type: Article

References (79)

1. Rostami E, Kashanian S, Azandaryani AH, Faramarzi H. Drug targeting using solid lipid nanoparticles. Chem. Phys. Lipids. 181, 56-61 (2014).
2. Fioramonti G, Bernegossi J, de Freitas LM, Fontana CR, Chorilli M. Nanotechnology-based drug delivery systems for photodynamic therapy of cancer: a review. Molecules 21(342), 1-18 (2016).
3. Subedi R, Kang K, Choi H. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur. J. Pharm. 37, 508-513 (2009).
4. Kuo Y, Chung C. Solid lipid nanoparticles comprising internal compritol 888ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Biointerfaces 88, 682-690 (2011).
5. Zhao L, Feng SS. Effects of lipid chain unsaturation and headgroup type on molecular interactions between paclitaxel and phospholipid within model biomembrane. J. Colloid Interface Sci. 285, 326-335 (2005).
6. Martin E, Capini C, Duggan E et al. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-κB. Arthritis Rheum. 56(7), 2255-2266 (2007).
7. Mo Y, Lim LY. Preparation and in vitro anti-cancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with Paclitaxel and isopropyl myristate. J. Control. Release 107, 30-42 (2005).
8. Ng SS, Figg WD, Sparrboom A. Taxane-mediated anti-angiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 64, 821-824 (2004).
9. Banerjee I, De K, Mukherjee D, Dey G, Chattopadhyay S. Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy. Acta Biomater. 38, 69-81 (2016).
10. Campos FC, Victorino VJ, Martins-pinge MC, Cecchini AL, Panis C, Cecchini R. Systemic toxicity induced by paclitaxel in vivo is associated with the solvent cremophor EL through oxidative stress-driven mechanisms. Food Chem. Toxicol. 68, 78-86 (2014).
11. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 52, 35-84 (1991).
12. Waugh WN, Trissel LA, Stella VJ. Stability, compatibility, and plasticizer extraction of Taxol injection diluted in infusion solutions and stored in various containers. Am. J. Hosp. Pharm. 48(7), 1520-1524 (1991).
13. Scheithauer W, Kornek G, Prager G et al. Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. J. Gastrointest. Oncol. 7(2), 234-238 (2015).
14. O'Connor R. The pharmacology of cancer resistance. Anticancer Res. 27, 1267-1272 (2007).
15. Ejendal KF, Hrycyna CA. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr. Protein Pept. Sci. 3(5), 503-511 (2002).
16. Meng S, Su B, Li W et al. Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes. Nanotechnology 21(41), 415103 (2010).
17. Jiang L, Li L, He X et al. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. Biomaterials 52, 126-139 (2015).
18. Ruttala HB, Ko YT. Liposome encapsulated albuminpaclitaxel nanoparticle for enhanced antitumor efficacy. Pharm. Res. 32, 1002-1016 (2015).
19. Zhang J, Han J, Zhang X, Jiang J, Xu M, Zhang D. Polymeric nanoparticles based on chitooligosaccharide as drug carriers for co-delivery of all-transretinoic acid and paclitaxel. Carbohydr. Polym. 129, 25-34 (2015).
20. Gao Y, Zhou Y, Zhao L et al. Enhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pHresponsive polymeric micelles. Acta Biomater. 23, 127-135 (2015).
21. Kang KW, Chun MK, Kim O, Subedi RK, Ahn SG, Yoon JH. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine 6(2), 210-213 (2010).
22. Kim J, Kim Y, Bae K, Park T, Lee J, Park K. Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticles. Mol. Pharm. 12(4), 1230-1241 (2015).
23. Chirio D, Gallarate M, Peira E et al. Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment. Eur. J. Pharm. Biopharm. 88(3), 746-758 (2014).
24. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631-651 (2002).
25. Amin L, Yeon J, Kee D, Soo S, An A. Surface modification and local orientations of surface molecules in nanotherapeutics. J. Control. Release 207, 131-142 (2015).
26. Cavalli R, Caputo O, Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur. J. Pharm. Sci. 10, 305-309 (2000).
27. Rivkin I, Cohen R, Koffler J, Melikhov D, Peer D, Margalit R. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 31, 7106-7114 (2010).
28. Key J, Dhawan D, Copper CL et al. Multicomponent, peptide-targeted glycol chitosan nanoparticles containing ferrimagnetic iron oxide nanocubes for bladder cancer multimodal imaging. Int. J. Nanomedicine 11, 4141-4155 (2016).
29. Benito AB, Aiertza MK, Marradi M et al. Functional single-chain polymer nanoparticles: targeting and imaging pancreatic tumors in vivo. Biomacromolecules 17(10), 3213-3221 (2016).
30. Li M, Tang Z, Zhang Y, Lv S, Li Q, Chen X. Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis. Acta Biomater. 18, 132-143 (2015).
31. Lokeshwar VB, Mirza S, Jordan A. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv. Cancer Res. 123, 35-65 (2014).
32. Lamberti M, Giovane G, Garzillo EM et al. Animal models in studies of cardiotoxicity side effects from antiblastic drugs in patients and occupational exposed workers. BioMed. Res. Inter. 2014, 240642 (2014).
33. Medema JP. Ahead, cancer stem cells: the challenges. Nat. Cell. Biol. 15, 338-344 (2014).
34. Yerushalni N, Margalit R. Hyaluronic acid-modified bioadhesive liposomes as local drug depots: effects of cellular and fluid dynamics on liposome retention at target sites. Arch. Biochem. Biophys. 349(1), 21-26 (1998).
35. Dragu DL, Necula LG, Bleotu C, Diaconu CC, Chivu-Economescu M. Therapies targeting cancer stem cells: current trends and future challenges. World J. Stem Cells 7, 1185-1201 (2015).
36. Yang XY, Li YX, Li M, Zhang L, Feng LX, Zhang N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett. 334, 338-345 (2013).
37. Journo-Gershfeld G, Kapp D, Shamay Y, Kopecek J, David A. Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma. Pharm. Res. 29, 1121-1133 (2012).
38. Qi LF, Xu ZR, Jiang X, Hu CH, Zou XZ. Preparation and antibacterial activity of chitosan nanoparticles. Carbohyd. Res. 339, 2693-2700 (2004).
39. Qu G, Yao Z, Zhang C, Wu X, Ping Q. PEG conjugated N-octyl-O-sulphate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation. Eur. J. Pharm. Sci. 37, 98-105 (2009).
40. Song S, Qi H, Xu J et al. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Pharm. Res. 31, 2988-3005 (2014).
41. Choi KY, Chung H, Min KH et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 31(1), 106-114 (2010).
42. Li Y, Zhao X, Zu Y, Zhang Y. Preparation and characterization of paclitaxel nanosuspension using novel emulsification method by combining high speed homogenizer and high pressure homogenization. Int. J. Pharm. 490(1-2), 324-333 (2015).
43. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm. 348(1-2), 137-145 (2008).
44. Wissing SA, Muller RH. A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles. Int. J. Cosmet. Sci. 23, 233-243 (2001).
45. Haidar ZS, Hamdy RC, Tabrizian M. Biocompatibility and safety of a hybrid core-shell nanoparticulate OP-1 delivery system intramuscularly administered in rats. Biomaterials 31(10), 2746-2754 (2010).
46. Ramasamy T, Haidar ZS, Tran TH et al. Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs. Acta Biomater. 10(12), 5516-5127 (2014).
47. Haidar ZS, Tabrizian M, Hamdy RC. A hybrid rhOP-1. delivery system enhances new bone regeneration and consolidation in a rabbit model of distraction osteogenesis. Growth Factors 28(1), 44-55 (2010).
48. Haidar ZS, Azari F, Hamdy RC, Tabrizian M. Modulated release of OP-1 and enhanced preosteoblast differentiation using a core-shell nanoparticulate system. J. Biomed. Mater. Res. A 92(3), 919-928 (2009).
49. Ramasamy T, Kim JO, Yong CS et al. Novel core-shell nanocapsules for the tunable delivery of bioactive rhEGF: formulation, characterization and cytocompatibility studies. J. Biomat. Tis. Eng. 9(5), 730-743 (2015).
50. Wang T, Ma X, Lei Y, Luo Y. Solid lipid nanoparticles coated with cross-linked polymeric double layer for oral delivery of curcumin. Colloids Surf. B Biointerfaces 148, 1-11 (2016)
51. Wang T, Hu Q, Zhou M, Xia Y, Nieh MP, Luo Y. Development of "all natural" layer-by-layer solid lipid nanoparticles by nano-spray drying technology. Eur. J. Pharm. Biopharm. 107, 273-285 (2016).
52. Ramasamy T, Tran TH, Choi JY et al. Layer-by-layer coated lipid-polymer hybrid nanoparticles designed for use in anticancer drug delivery. Carbohydr. Polym. 102, 653-661 (2014).
53. Li F, Zhao X, Wang H et al. Multiple layer-by-layer lipidpolymer hybrid nanoparticles for improved FOLFIRINOX chemotherapy in pacreatic tumor models. Adv. Funct. Mater. 25(5), 788-798 (2014).
54. Das RK, Kasoju N, Bora U. Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine 6, 153-160 (2010).
55. Liu Y, Pan J, Feng SS. Nanoparticles of lipid momolayer shell and biodegradable polymer core for controlled release of Paclitaxel: effects of surfactants on particle size, characteristics and in vitro performance. Int. J. Pharm. 395, 243-250 (2010).
56. Mader K, Mehnert W. Approaches, methods and applications. In: Lipospheres in Drug Targets and Delivery. Nastruzzi C (Ed.). Taylor and Francis Group, CRC Press, NY, USA, 1-22 (2004).
57. Vitorino C, Carvalho FA, Almeida AJ, Sousa JJ, Pais ACC. The size of solid lipid nanoparticles: an interpretation from experimental design. Colloids Surf. B Biointerfaces 84, 117-130 (2011).
58. Zhang J, Fan Y, Smith E. Experimental design for the optimization of lipid nanoparticles. J. Pharm. Sci. 98(5), 1813-1819 (2009).
59. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles of tretinion: potential in topical delivery. Int. J. Pharm. 345, 163-171 (2007).
60. Schubert MA, Muller-Goymann CC. Characteristics of surface modified solid lipid nanoparticles: influence of lecithin and non-ionic emulsifier. Eur. J. Pharm. Biopharm. 61, 77-86 (2005).
61. Attama AA, Muller-Goymann CC. Effect of beeswax modification on the lipid matrix and solid lipid nanoparticle crystallinity. Colloid Surf. A 315, 189-195 (2008).
62. Vijayan V, Aafreen S, Sakthivel S, Reddy KR. Formulation and characterization of solid lipid nanoparticles loaded Neem oil for topical treatment of acne. J. Acute Dis. 2(4), 282-286 (2013).
63. Westesen K, Wehler T. Characterization of a submicron sized oil-in-water emulsion. Colloid. Surf. A. 78, 115-123 (1993).
64. Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf. B Biointerfaces 88, 483-489 (2013).
65. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic environment of human tumors: a review. Cancer Res. 49, 6449-6465 (1989).
66. Yin T, Wang L, Yin L, Zhou J, Huo M. Biomaterials codelivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. Biomaterials 61, 10-25 (2015).
67. Chen C, Hu H, Qiao M et al. Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel. Int. J. Pharm. 480(1-2), 116-127 (2015).
68. Li F, Wu F, Zhang H, Li F, Gu C, Yang Q. Antitumor drug Paclitaxel-loaded pH-sensitive nanoparticles targeting tumor extracellular pH. Carbohydr. Polym. 77, 773-778 (2009).
69. Muller RH, Ruhl D, Runge SA. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int. J. Pharm. 144, 115-121 (1996).
70. Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28(12), 2137-2146 (2007).
71. Serpe L, Catalano MG, Cavalli R et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm. 58, 673-680 (2004).
72. Youm I, Agrahari V, Murowchick JB, Youan BC. Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells. Pharm. Res. 31, 2439-2452 (2014).
73. Singh SP, Sharma M, Gupta PK. Cytotoxicity of curcumin silica nanoparticle complexes conjugated with hyaluronic acid on colon cancer cells. Int. J. Biol. Macromol. 74, 162-170 (2015).
74. Bhushan S, Kakkar V, Chandra H, Mondhe DM. The augmented anticancer potential of AP9-cd loaded solid lipid nanoparticles in human leukemia Molt-4 cells and experimental tumor. Chem. Biol. Interact. 244, 84-93 (2016).
75. Parveen R, Ahmad R, Igbal Z, Samim M, Ahmad S. Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies. Drug Dev. Ind. Pharm. 40(9), 1206-1212 (2014).
76. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16(10), 1217-1226 (2002).
77. Lowry MB, Duchemin AM, Robinson JM, Anderson CL. Functional separation of pseudopod extension and particle internalization during Fc gamma receptor-mediated phagocytosis. J. Exp. Med. 187, 161-176 (1998).
78. Tran TH, Choi JY, Ramasamy T et al. Hyaluronic acidcoated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Carbohydr. Polym. 114, 407-415 (2014).
79. Shen H, Shi S, Zhang Z, Gong T, Sun X. Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells. Theranostics 5(7), 755-771 (2015).